| Literature DB >> 24090071 |
Takako Tanaka1, Masaharu Asai, Yorihide Yanagita, Tsuyoshi Nishinakagawa, Naomi Miyamoto, Kenji Kotaki, Yudai Yano, Ryo Kozu, Sumihisa Honda, Hideaki Senjyu.
Abstract
BACKGROUND: Air pollution is known to be a leading cause of respiratory symptoms. Many cross-sectional studies reported that air pollution caused respiratory disease in Japanese individuals in the 1960s. Japan has laws regulating air pollution levels and providing compensation for victims of pollution-related respiratory disease. However, long-term changes in respiratory function and symptoms in individuals who were exposed to air pollution in the 1960s have not been well studied. This study aimed to investigate longitudinal respiratory function and symptoms in older, non-smoking, long-term officially-acknowledged victims of pollution-related illness.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24090071 PMCID: PMC3765588 DOI: 10.1186/1471-2458-13-766
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Time required for certification of pollution-related illness
| Chronic bronchitis | 24 months | 48 months | 36 months |
| Asthma | 12 months | 30 months | 18 months |
| Emphysema | 36 months | 66 months | 52 months |
a) Individual who resided in a designated area prior to 1973.
b) Individual who did not reside in a designated area, but spent at least 8 hours per day in a designated area.
c) Individual who resided in a designated area, then relocated but continued to work in a designated area for at least 8 hours per day.
Figure 1Flow chart showing selection of the study subjects. The study included officially-acknowledged victims of pollution-related illness in Kurashiki who were aged 65 years or older in 2009, and for whom the required data for statistical analysis were available.
Figure 2Sulfur dioxide and nitrogen dioxide concentrations from 1965 to 2009 relative to standard values.
Patient characteristics at the time of certification
| Age (years) | 49.6 ± 8.5 | 51.4 ± 8.9 | <.05 |
| Chronic bronchitis | 88 (56.4%) | 271 (66.6%) | 0.395 |
| Asthma | 66 (42.3%) | 135 (33.2%) | |
| Emphysema | 2 (1.3%) | 1 (0.2%) | |
| FEV1 (l) | 2.51 ± 0.75 | 1.93 ± 0.50 | <.001 |
| FEV1 % predicted | 77 ± 21 | 89 ± 21 | <.001 |
| FVC (l) | 3.50 ± 0.77 | 2.59 ± 0.52 | <.001 |
| FVC % predicted | 91 ± 17 | 100 ± 16 | <.01 |
| VC (l) | 3.67 ± 0.74 | 2.71 ± 0.51 | <.001 |
| VC % predicted | 102 ± 18 | 108 ± 17 | <.01 |
| FEV1/FVC (%) | 71.4 ± 14.8 | 74.5 ± 10.9 | <.05 |
| Dyspnea | 32 (20.5%) | 79 (19.4%) | 0.361 |
| | 91 (58.3%) | 266 (65.4%) | |
| | 28 (17.9%) | 53 (13.0%) | |
| | 3 (1.9%) | 5 (1.2%) | |
| | 1 (0.6%) | 0 (0%) | |
| Wheeze | 47 (30.1%) | 161 (39.6%) | <.05 |
| | 59 (37.8%) | 156 (38.3%) | |
| | 40 (25.6%) | 75 (18.4%) | |
| | 8 (5.1%) | 13 (3.2%) | |
| | 1 (0.6%) | 1 (0.2%) | |
| Cough and sputum | 13 (8.3%) | 24 (5.9%) | 0.623 |
| | 87 (55.8%) | 228 (56.0%) | |
| | 49 (31.4%) | 144 (35.4%) | |
| | 6 (3.8%) | 8 (2.0%) | |
| 1 (0.6%) | 1 (0.2%) |
FEV forced expiratory volume in 1 second, FVC forced vital capacity, VC vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation or number (%).
Male versus female: Mann–Whitney U test, Kruskal Wallis test.
Comparisons of respiratory function in 2000 and 2009
| | | | |
| Age (years) | 67.0 ± 7.4 | 75.5 ± 7.3 | <.001 |
| FEV1 (l) | 2.08 ± 0.68 | 1.82 ± 0.60 | <.001 |
| FEV1 % predicted | 76 ± 23 | 75 ± 23 | 0.43 |
| FVC (l) | 3.01 ± 0.76 | 2.67 ± 0.74 | <.001 |
| FVC % predicted | 90 ± 21 | 87 ± 22 | <.01 |
| VC (l) | 3.18 ± 0.73 | 2.84 ± 0.72 | <.001 |
| VC % predicted | 98 ± 21 | 92 ± 21 | <.001 |
| FEV1/FVC (%) | 68.7 ± 13.7 | 68.4 ± 13.2 | 0.09 |
| | |||
| Age (years) | 68.8 ± 7.8 | 77.4 ± 7.8 | <.001 |
| FEV1 (l) | 1.59 ± 0.44 | 1.39 ± 0.46 | <.001 |
| FEV1 % predicted | 93 ± 28 | 91 ± 23 | <.01 |
| FVC (l) | 2.23 ± 0.52 | 1.96 ± 0.56 | <.001 |
| FVC % predicted | 101 ± 21 | 100 ± 25 | 0.62 |
| VC (l) | 2.31 ± 0.54 | 2.04 ± 0.57 | <.001 |
| VC % predicted | 105 ± 21 | 99 ± 24 | <.001 |
| FEV1/FVC (%) | 71.3 ± 10.0 | 71.0 ± 11.3 | 0.31 |
FEV forced expiratory volume in 1 second, FVC forced vital capacity, VC vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
2000 versus 2009: Wilcoxon signed-rank test.
Mean annual changes in the yearly consecutive spirometry data in males and females from 2000 to 2009
| FEV1 (ml) | −27.6 ± 37.8 | −23.9 ± 24.9 | 0.239 |
| FEV1 % predicted | −0.12 ± 1.48 | −0.20 ± 1.66 | 0.221 |
| FVC (ml) | −38.0 ± 47.2 | −31.8 ± 34.3 | 0.104 |
| FVC % predicted | −0.30 ± 1.51 | −0.22 ± 1.87 | 0.354 |
| VC (ml) | −40.6 ± 44.2 | −32.7 ± 33.9 | <.05 |
| VC % predicted | −0.65 ± 1.39 | −0.65 ± 1.59 | 0.541 |
| FEV1/FVC (%) | −0.01 ± 0.77 | −0.05 ± 0.75 | 0.979 |
FEV forced expiratory volume in 1 second, FVC forced vital capacity, VC vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
The regression coefficients for the individual mean annual changes in pulmonary function were calculated using simple linear regression analysis.
Male versus female: Mann–Whitney U test, Kruskal-Wallis test.
Respiratory symptoms in 2000 and 2009
| Score | | |||||
| Dyspnea | 1 | 10 | (6.4%) | 17 | (10.9%) | <.05 |
| | 2 | 91 | (58.3%) | 92 | (59.0%) | |
| | 3 | 50 | (32.1%) | 37 | (23.7%) | |
| | 4 | 5 | (3.2%) | 10 | (6.4%) | |
| | 5 | 0 | (0%) | 0 | (0%) | |
| Wheeze | 1 | 40 | (25.6%) | 45 | (28.8%) | 0.84 |
| | 2 | 60 | (38.5%) | 53 | (34.0%) | |
| | 3 | 45 | (28.8%) | 46 | (29.5%) | |
| | 4 | 11 | (7.1%) | 12 | (7.7%) | |
| | 5 | 0 | (0%) | 0 | (0%) | |
| Cough and sputum | 1 | 0 | (0%) | 2 | (1.3%) | 0.87 |
| | 2 | 77 | (49.4%) | 75 | (48.1%) | |
| | 3 | 72 | (46.2%) | 72 | (46.2%) | |
| | 4 | 7 | (4.5%) | 6 | (3.8%) | |
| | 5 | 0 | (0%) | 1 | (0.6%) | |
| Score | | |||||
| Dyspnea | 1 | 35 | (8.6%) | 41 | (10.1%) | <.01 |
| | 2 | 274 | (67.3%) | 282 | (69.5%) | |
| | 3 | 84 | (20.6%) | 73 | (18.0%) | |
| | 4 | 13 | (3.2%) | 10 | (2.5%) | |
| | 5 | 1 | (0.2%) | 0 | (0%) | |
| Wheeze | 1 | 132 | (32.4%) | 156 | (38.3%) | <.01 |
| | 2 | 159 | (39.1%) | 137 | (33.7%) | |
| | 3 | 95 | (23.3%) | 97 | (23.8%) | |
| | 4 | 21 | (5.1%) | 17 | (4.2%) | |
| | 5 | 0 | (0%) | 0 | (0%) | |
| Cough and sputum | 1 | 6 | (1.5%) | 13 | (3.2%) | 0.97 |
| | 2 | 204 | (50.1%) | 201 | (49.4%) | |
| | 3 | 183 | (45.0%) | 182 | (44.7%) | |
| | 4 | 13 | (3.2%) | 11 | (2.7%) | |
| 5 | 1 | (0.2%) | 0 | (0%) | ||
Values are presented as number (%).
2000 versus 2009: Wilcoxon signed-rank test.
Mean annual changes in the yearly consecutive spirometry data in subjects with and without worsening of dyspnea
| | |||
| FEV1 (ml) | −25.6 ± 35.5 | −43.2 ± 51.3 | 0.52 |
| FEV1 % predicted | −0.12 ± 1.41 | −0.09 ± 2.01 | 0.63 |
| FVC (ml) | −35.0 ± 43.0 | −58.5 ± 64.8 | 0.29 |
| FVC % predicted | −0.23 ± 1.41 | −0.93 ± 2.02 | 0.32 |
| VC (ml) | −39.1 ± 43.4 | −52.9 ± 49.6 | 0.28 |
| VC % predicted | −0.60 ± 1.37 | −1.00 ± 1.60 | 0.51 |
| FEV1/FVC (%) | −0.04 ± 0.72 | −0.24 ± 1.10 | 0.07 |
| n = 367 | n = 40 | | |
| FEV1 (ml) | −23.1 ± 25.1 | −30.9 ± 22.3 | <.01 |
| FEV1 % predicted | −0.27 ± 1.69 | −0.40 ± 1.29 | <.001 |
| FVC (ml) | −31.1 ± 35.0 | −38.5 ± 26.3 | <.05 |
| FVC % predicted | −0.19 ± 1.91 | −0.50 ± 1.41 | <.05 |
| VC (ml) | −31.4 ± 34.0 | −44.6 ± 30.5 | <.05 |
| VC % predicted | −0.60 ± 1.59 | −1.27 ± 1.45 | <.001 |
| FEV1/FVC (%) | −0.04 ± 0.73 | −0.16 ± 0.90 | 0.13 |
FEV forced expiratory volume in 1 second, FVC forced vital capacity, VC vital capacity,
FEV1/FVC (%) forced expiratory volume in 1 second.
Values are presented as mean ± standard deviation.
Without worsening versus with worsening: Mann–Whitney U test.